Formulation Development
uniQure Announces Enrollment of Next Two Patients in Phase 1/2 Clinical Trial
uniQure N.V. recently announced that two additional patient procedures have been completed in the Phase 1/2 clinical trial of AMT-130 for the treatment of Huntington’s…
Mogrify Introduces Platform to Systematically Identify Epigenetic Switches Driving Cell Identity & Cell Maintenance
Mogrify Limited recently announced the introduction of EpiMOGRIFY. The platform models the epigenetic state of the cell to predict the switches important for cell identity,…
NapaJen Pharma Reports Positive Results From Phase 1 Clinical Trial of Novel RNAi Therapeutic
NapaJen Pharma, Inc. recently announced positive results from the company’s Phase 1 first-in-human clinical trial of NJA-730. NJA-730 is a novel immunosuppressive therapeutic that combines…
Cambrex Completes Major Expansion of Solid Form Screening Facility
Cambrex recently announced the completion of an expansion of its solid form screening and crystallization process development facility in Edinburgh, Scotland. This major expansion project…
WEBINAR SERIES ALERT - Learn About Complex Parenteral Drug Delivery From Evonik Industry Experts - Free Oct-Nov Webinar Series
As a global CDMO leader for advanced drug delivery, Evonik invites you to join us for a webinar series on parenteral drug delivery. More than a dozen technical experts from Evonik will review….
Scientific Management of Pharmaceutical Container Closure & Delivery Device Compatibility
Diane Paskiet says the relationship between pharmaceutical products and CC/DD is best managed through a rich science-based approach that factors in potential risk and is adapted early in the development process.
Mustang Bio Licenses LentiBOOST Technology From SIRION Biotech
Mustang Bio, Inc. and SIRION Biotech GmbH recently announced a licensing agreement under which Mustang has acquired rights to SIRION’s LentiBOOST technology for the development…
Evaxion Biotech Launches New AI Powered Platform to Enable Faster Response to Emerging Viral Pandemics
Evaxion Biotech recently announced it has received approximately $800,000 in funding from Innovation Fund Denmark for the development of its new RAVEN platform, an integral…
Catalent Launches OneXpress Solution to Accelerate Oral Dosage Products From Clinic to Launch
Catalent recently announced the launch of its new OneXpress service for the integrated development, scale up, and manufacturing of new oral solid dosage forms. The…
AiViva Biopharma Initiates Phase 1/2 Clinical Trial of AIV001 for Nonmelanoma Skin Cancer
AiViva Biopharma Inc. recently announced it has begun dosing patients diagnosed with superficial or nodular basal cell carcinoma (BCC) with AIV001. AIV001 is AiViva’s novel…
Proveris Scientific Research Collaboration: New Generation Technologies for Improved Measurement of Pharmaceutical Aerosols
Proveris Scientific Corporation recently announced its research collaboration with The University of Sydney and Macquarie University on a project to develop a new generation of technologies for improving….
Recipharm Signs Agreement With Arcturus Therapeutics to Support the Manufacture of LUNAR-COV19 (ARCT-021) Vaccine Candidate
Recipharm has recently entered into an agreement with Arcturus Therapeutics, a leading US-based clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and….
First Commercial Drug Manufactured Via Ajinomoto Bio-Pharma Services’ AJIPHASE Technology Receives FDA Approval
Ajinomoto Bio-Pharma Services recently announce the US FDA has approved the first commercial drug manufactured via Aji Bio-Pharma’s proprietary AJIPHASE production process…..
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion
Bristol Myers Squibb and MyoKardia, Inc. recently announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or….
Evonik Launches New Oral Drug Delivery Technology for Enteric Protection & Rapid Release in the Upper Small Intestine
Evonik has recently launched an advanced oral drug delivery technology that provides enteric protection followed by rapid, homogeneous release for effective….
PLATFORM TECHNOLOGY - Morphomer(TM) & SupraAntigen(TM) Platforms: Targeting Misfolded Proteins in Neurodegenerative Disorders
Andrea Pfeifer, PhD, details the efforts to develop the therapeutic and diagnostic tools necessary to enable precision medicine approaches targeting the right protein, at the right time, in the right patient.
FORMULATION FORUM - Parenteral Sustained Delivery of ASD-005 Liposomal Formulation: A Case Study in Applications of Lipid-Based Nanoparticle Carriers
Jim Huang, PhD, presents an investigation aimed at studying the administration of a liposomal form of a third-generation β-blocker, ASD-005, by injectable route of administration to efficiently manage emergency hypertension and congestive heart failure.
ASSAY DEVELOPMENT - Case Study: How Custom Assay Development Helped Spur Precision Medicine Research in Multiple Myeloma
Steven Gross, MS, provides a behind-the-scenes look at the CMMC assay development process (from 2010 through today) to show how pharmaceutical companies can effectively partner with a laboratory to design customized assays that complement their drug discovery and development programs.
PEGYLATION - PEGylation - Three Decades of Product Approvals & Technology Development
Esay Okutgen, PhD, Alper Orhan, MSc, and Josef Bossart, PhD, believe with the 30-year anniversary of the first product approval using PEG (polyethylene oxide polymer) conjugation, it seems an appropriate occasion to review the evolution of the technology (PEGylation) and subsequent product approvals.
CDMO CASE STUDY - AJILITY: Streamlining Drug Product Manufacturing
Dustin Campbell says the AJILITY platform takes the burden off clients and allows his company to drive, manage, and support their drug product manufacturing, maximizing speed and success, while prioritizing these programs are driven to completion.
